TY - JOUR
T1 - Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations
T2 - Recommendations From the International Association for the Study of Lung Cancer Pathology Committee
AU - IASLC Pathology Committee
AU - Chou, Teh Ying
AU - Dacic, Sanja
AU - Wistuba, Ignacio
AU - Beasley, Mary Beth
AU - Berezowska, Sabina
AU - Chang, Yeun Chung
AU - Chung, Jin Haeng
AU - Connolly, Casey
AU - Han, Yuchen
AU - Hirsch, Fred R.
AU - Hwang, David M.
AU - Janowczyk, Andrew
AU - Joubert, Philippe
AU - Kerr, Keith M.
AU - Lin, Dongmei
AU - Minami, Yuko
AU - Mino-Kenudson, Mari
AU - Nicholson, Andrew G.
AU - Papotti, Mauro
AU - Rekhtman, Natasha
AU - Roden, Anja C.
AU - von der Thüsen, J. H.
AU - Travis, William
AU - Tsao, Ming Sound
AU - Yatabe, Yasushi
AU - Yeh, Yi Chen
AU - Bubendorf, Lukas
AU - Chang, Wei Chin
AU - Denninghoff, Valeria
AU - Fernandes Tavora, Fabio Rocha
AU - Hayashi, Takuo
AU - Hofman, Paul
AU - Jain, Deepali
AU - Kim, Tae Jung
AU - Lantuejoul, Sylvie
AU - Le Quesne, John
AU - Lopez-Rios, Fernando
AU - Matsubara, Daisuke
AU - Noguchi, Masayuki
AU - Radonic, Teodora
AU - Saqi, Anjali
AU - Schalper, Kurt
AU - Shim, Hyo Sup
AU - Sholl, Lynette
AU - Weissferdt, Annikka
AU - Cooper, Wendy A.
N1 - Publisher Copyright:
© 2024 International Association for the Study of Lung Cancer
PY - 2024
Y1 - 2024
N2 - Introduction: With the implementation of low-dose computed tomography screening, multiple pulmonary tumor nodules are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging on a daily basis in clinical practice. In the presence of multiple carcinomas, especially adenocarcinomas, pathologically determined to be of pulmonary origin, the distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is important for staging, management, and prognostication. Methods: We systemically reviewed various means that aid in the differentiation between SPLCs and IPMs explored by histopathologic evaluation and molecular profiling, the latter includes DNA microsatellite analysis, array comparative genomic hybridization, TP53 and oncogenic driver mutation testing and, more recently, with promising effectiveness, next-generation sequencing comprising small- or large-scale multi-gene panels. Results: Comprehensive histologic evaluation may suffice to differentiate between SPLCs and IPMs. Nevertheless, molecular profiling using larger-scale next-generation sequencing typically provides superior discriminatory power, allowing for more accurate classification. On the basis of the literature review and expert opinions, we proposed a combined four-step histologic and molecular classification algorithm for addressing multiple pulmonary tumor nodules of adenocarcinoma histology that encourages a multidisciplinary approach. It is also noteworthy that new technologies combining machine learning and digital pathology may develop into valuable diagnostic tools for distinguishing SPLCs from IPMs in the future. Conclusions: Although histopathologic evaluation is often adequate to differentiate SPLCs from IPMs, molecular profiling should be performed when possible, especially in cases with tumors exhibiting similar morphology. This manuscript summarized the previous efforts in resolving the current challenges and highlighted the recent progress in the differentiation methods and algorithms used in categorizing multiple lung adenocarcinomas into SPLCs or IPMs, which are becoming more and more critical in precision lung cancer management.
AB - Introduction: With the implementation of low-dose computed tomography screening, multiple pulmonary tumor nodules are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging on a daily basis in clinical practice. In the presence of multiple carcinomas, especially adenocarcinomas, pathologically determined to be of pulmonary origin, the distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is important for staging, management, and prognostication. Methods: We systemically reviewed various means that aid in the differentiation between SPLCs and IPMs explored by histopathologic evaluation and molecular profiling, the latter includes DNA microsatellite analysis, array comparative genomic hybridization, TP53 and oncogenic driver mutation testing and, more recently, with promising effectiveness, next-generation sequencing comprising small- or large-scale multi-gene panels. Results: Comprehensive histologic evaluation may suffice to differentiate between SPLCs and IPMs. Nevertheless, molecular profiling using larger-scale next-generation sequencing typically provides superior discriminatory power, allowing for more accurate classification. On the basis of the literature review and expert opinions, we proposed a combined four-step histologic and molecular classification algorithm for addressing multiple pulmonary tumor nodules of adenocarcinoma histology that encourages a multidisciplinary approach. It is also noteworthy that new technologies combining machine learning and digital pathology may develop into valuable diagnostic tools for distinguishing SPLCs from IPMs in the future. Conclusions: Although histopathologic evaluation is often adequate to differentiate SPLCs from IPMs, molecular profiling should be performed when possible, especially in cases with tumors exhibiting similar morphology. This manuscript summarized the previous efforts in resolving the current challenges and highlighted the recent progress in the differentiation methods and algorithms used in categorizing multiple lung adenocarcinomas into SPLCs or IPMs, which are becoming more and more critical in precision lung cancer management.
KW - Adenocarcinomas
KW - Histopathology
KW - Intrapulmonary metastases
KW - Multiple pulmonary tumor nodules
KW - Next generation sequencing
KW - Separate primary lung carcinomas
UR - http://www.scopus.com/inward/record.url?scp=85212333505&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2024.11.016
DO - 10.1016/j.jtho.2024.11.016
M3 - Article
C2 - 39579981
AN - SCOPUS:85212333505
SN - 1556-0864
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
ER -